ENANTA PHARMACEUTICALS, INC Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net
ENANTA PHARMACEUTICALS, INC (ENTA) reported Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net of $213.00 thousand for the 12-month period ending 2017-09-30, per its 10-K filed 2019-11-27.
Discontinued › Notes › Compensation Related Costs
us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet · last filed 2019-11-27
- ENANTA PHARMACEUTICALS, INC adjustment to additional paid in capital, income tax effect from share-based compensation, net for fiscal 2017 was $213.00K, a 87.81% decline from fiscal 2016.
- ENANTA PHARMACEUTICALS, INC adjustment to additional paid in capital, income tax effect from share-based compensation, net for fiscal 2016 was $1.75M, a 3.69% decline from fiscal 2015.
- ENANTA PHARMACEUTICALS, INC adjustment to additional paid in capital, income tax effect from share-based compensation, net for fiscal 2015 was $1.81M, a 1549.09% increase from fiscal 2014.
- ENANTA PHARMACEUTICALS, INC adjustment to additional paid in capital, income tax effect from share-based compensation, net for fiscal 2014 was $110.00K.
| Period end | Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net 12 month | Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net 12 month as first filed |
|---|---|---|
| 2017-09-30 | $213.00K 10-K · filed 2019-11-27 | |
| 2016-09-30 | $1.75M 10-K · filed 2018-11-29 | |
| 2015-09-30 | $1.81M 10-K · filed 2017-12-11 | |
| 2014-09-30 | $110.00K 10-K · filed 2016-12-09 | -$110.00K 10-K · filed 2014-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |